Jane Street’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Jane Street’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-16,000	Closed	-$1.72M	–	5039
2016 Q4	$1.72M	Buy	16,000 +6,000	+60%	+$701K	0.01%	1459
2016 Q3	$1.25M	Buy	+10,000	New	+$1.18M	0.01%	1681

Other funds holding CBPO

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capstone Investment Advisors New York $57.4B AUM 26.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCP

Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Jane Street's CBPO Position: Q4 2020 in Review

Jane Street sold out of China Biologic Products Holdings, Inc. (CBPO) in Q4 2020, closing a stake of 2,280 shares — an estimated $253K sold.

Jane Street first reported a position in CBPO in Q2 2014 and held it in 14 quarters. The position peaked at $3.08M in Q3 2016. 89 funds tracked by Wall St. Rank hold CBPO as of Q4 2020.

Jane Street reported no remaining China Biologic Products Holdings, Inc. position as of Q4 2020 after selling out during the quarter.
Jane Street sold 2,280 China Biologic Products Holdings, Inc. shares in Q4 2020, an estimated $253K.
Jane Street first reported a position in China Biologic Products Holdings, Inc. in Q2 2014 and held it in 14 quarters.
Jane Street's China Biologic Products Holdings, Inc. position peaked at $3.08M in Q3 2016.
89 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q4 2020.

Based on Jane Street's 13F filing for Q4 2020, filed 17 Feb 2021.